Compare Crispr Therapeutics AG (CRSP) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PPG Industries, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while PPG Industries, Inc. trades at $114.66 (market cap $25.56B). The key difference: PPG Industries, Inc. is far larger — about 5.1× Crispr Therapeutics AG's market cap, and PPG Industries, Inc. pays a 2.48% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PPG | |
|---|---|---|
Market Cap | $4.97B | $25.56B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $131.56 |
52-Week Low | $44.34 | $94.34 |
Enterprise Value | $3.32B | $31.66B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
PPG Industries trades at $113.84, down 2.5% on the day, with a bullish technical signal despite near-term volatility. The stock shows strong profitability with a net margin of 9.83% and ROE of 21.09%, supported by consistent earnings beats in recent quarters. Recent news highlights innovation in aerospace and marine coatings, alongside a sustainable dividend profile. Valuation ratios appear reasonable with a P/E of 16.31 and P/S of 1.6.
The outlook remains positive given analyst consensus favoring a buy rating and a $131.75 price target, implying significant upside. Risks include volume softness and margin pressure, but robust cash flow and strategic innovations provide a cushion. The stock presents a value opportunity with growth catalysts from new product launches and market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
